The FDA has approved a second chimeric antigen receptor (CAR) T-cell therapy for cancer: Kite Pharma's axicabtagene ciloleucel (Yescarta) for the treatment of certain types of refractory large B-cell lymphoma, the agency announced.
The International Pharmaceutical Networking Exhibition (CPhI Worldwide 2017), will be held at Ludwig-Erhard-Anlage 1 in Messe Frankfurt, Germany from the 24th to the 26th of October 2017. As the leading global pharmaceutical & medical device B2B online platform, Ddu is going to attend the exhibition, showcasing the new Chinese cross-border medical trade method to Germany and the whole world.
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from pre-existing moles, but the majority of them come from sources unknown - until now.
AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.
Takeda Pharmaceutical Company Limited and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).
The pill form of the drug semaglutide is worth pursuing as a way to control blood sugar in patients with type 2 diabetes, say researchers.
A recent study investigates the ability of an asthma drug to reduce levels of α-synuclein, a protein believed to contribute to the development of Parkinson’s disease.
Neurotech International Ltd has successfully raised $4 million via a placement of shares at $0.20 each to drive its ongoing commercialisation of the Mente Autism device.
A study of the global prevalence of fetal alcohol spectrum disorder (FASD) estimates that it affects as many as 8 out of 10,000 children, highlighting the need to improve public education about the potential harm of drinking alcohol during pregnancy.
US regulators have accepted an application by AstraZeneca and MedImmune to expand the scope of Imfinzi (durvalumab) to include patients with a certain form of lung cancer.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.